Skip to content

No results found

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

CYTK Cytokinetics Inc.
$61.44 2.35% +1.41
Notify me if price changes either direction
Interactive Brokers Logotype

Buy CYTK stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 7.4B
Enterprise value 8.1B
Trailing PE -9.3990825688073
Forward PE -12.36665
PEG Ratio -0.49345183486239
Enterprise to EBITDA -13.391
Enterprise to revenue 91.589
Price to book MRQ -11.409540238772
Price to sales TTM 82.85325

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2025-12-31
Revenue (TTM) 88.0M
EBITDA -602132992
Diluted EPS TTM -6.54
Total Cash (MRQ) 882.2M
Current ratio (MRQ) 4.529
Operating Cash Flow (TTM) -510008992

CYTK trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent CYTK News

Home

No results found

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.